Portola Pharmaceuticals LLC - Company Profile
Powered by 
All the data and insights you need on Portola Pharmaceuticals LLC in one report.
$295
- Save hours of research time and resources with
our up-to-date Portola Pharmaceuticals LLC Strategy Report
- Understand Portola Pharmaceuticals LLC position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Portola Pharmaceuticals LLC patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CN108883160B | Grant | 因子XA解毒剂的冻干制剂 | A61K38/4846; A61K47/183; A61K47/26; A61K9/0019; A61K9/19; A61P39/02; A61P7/00; A61P9/00; C07K14/00; C12N9/6432; C12Y304/21006 | June 28, 2022 |
| BRPI0910921B1 | Grant | Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores | A61K31/506; A61P35/00; A61P9/00; C07D239/48; C07D401/12; C07D403/12; C07D407/12; C07D409/12; C07D413/12; C07D417/12; C07D471/04; C07D487/04 | June 21, 2022 |
| LTC3078743I2 | Grant | ANTIKŪNAI XA VEIKSNIO INHIBITORIAMS IR JŲ NAUDOJIMO BŪDAI | A61K38/00; A61K38/4826; A61K38/4833; A61K38/4846; A61K38/4853; A61K39/00; A61K47/60; A61P39/02; A61P7/00; A61P7/02; A61P7/04; C07K14/435; C12N9/6432; C12Y304/21006 | June 10, 2022 |
| ES2913119T3 | Grant | Cerdulatinib para tratar mieloma | A61K31/506; A61K45/06; A61P35/02 | May 31, 2022 |
| JP7047148B2 | Grant | 骨髄腫を治療するためのセルデュラチニブ（ＣＥＲＤＵＬＡＴＩＮＩＢ） | A61K31/506; A61K45/06; A61P35/02 | April 04, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer